{"classes":[{"categories":[{"measurements":[{"comment":"Could not be estimated due to the insufficient number of events.","groupId":"OG000","lowerLimit":"10.85","upperLimit":"NA","value":"NA"},{"comment":"Could not be estimated due to the insufficient number of events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"11.97"},{"comment":"Could not be estimated due to the insufficient number of events.","groupId":"OG002","lowerLimit":"1.64","upperLimit":"NA","value":"NA"},{"comment":"Could not be estimated due to the insufficient number of events.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"Onset of First Response"},{"categories":[{"measurements":[{"comment":"Could not be estimated due to the insufficient number of events.","groupId":"OG000","lowerLimit":"2.10","upperLimit":"NA","value":"3.68"},{"comment":"Could not be estimated due to the insufficient number of events.","groupId":"OG001","lowerLimit":"1.68","upperLimit":"NA","value":"4.41"},{"comment":"Could not be estimated due to the insufficient number of events.","groupId":"OG002","lowerLimit":"1.64","upperLimit":"NA","value":"3.29"},{"comment":"Could not be estimated due to the insufficient number of events.","groupId":"OG003","lowerLimit":"1.64","upperLimit":"NA","value":"2.17"}]}],"title":"Onset of Best Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"Time to onset of first response was defined as the time between the date of first investigational product (IP) dose and the earliest date any response (CR, PR, mCR, or HI) was first observed. Participants who did not achieve any defined response during the treatment period were censored at the date of treatment discontinuation, disease progression, or death, whichever occurred first. Best response is the best recorded response or treatment outcome from the start of the study treatment until the end of the study treatment taking into account the requirements for confirmation of response.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were given oral azacitidine (AZA) 100 mg, 150 mg, or 200 mg tablets twice daily (BID) on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.","id":"OG000","title":"Stable Disease (SD) Cohort: Oral Azacitidine"},{"description":"Participants were given oral azacitidine 100 mg, 150mg, or 200mg tablets BID on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.","id":"OG001","title":"Progressive Disease (PD) Cohort: Oral Azacitidine"},{"description":"Participants received 100 mg oral azacitidine (AZA) tablets BID on days 1 to 14 or days 1 to 21 of each 28-day treatment cycle and durvalumab (Durva) 1500 mg by intravenous infusion on day 1 of each 28-day treatment cycle; participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.","id":"OG002","title":"Stable Disease Cohort: Oral Azacitidine and Durvalumab"},{"description":"Participants received 100 mg oral azacitidine tablets BID on days 1 to 14 or days 1 to 21 of each 28-day treatment cycle and durvalumab 1500 mg by intravenous infusion on day 1 of each 28-day treatment cycle; participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.","id":"OG003","title":"Progressive Disease Cohort: Oral Azacitidine and Durvalumab"}],"paramType":"MEDIAN","populationDescription":"The ITT population included all enrolled participants who received at least one dose of IP.","reportingStatus":"POSTED","timeFrame":"Response was assessed every 2 cycles following treatment during the first 6 cycles, then every 3 cycles thereafter; median duration of treatment = 5.26 and 3.81 months for SD/PD for oral AZA arms respectively, and 1.84 months for AZA and Durva SD/PD arms","title":"Kaplan Meier Estimate of Time to Onset of First and Best Response","type":"SECONDARY","unitOfMeasure":"Months"}